09:53 AM EST, 03/06/2025 (MT Newswires) -- BridgeBio Pharma ( BBIO ) shares were falling past 5% in recent Thursday trading after KKR Genetic Disorder disclosed the sale of 6 million BridgeBio shares in a regulatory filing.

KKR Genetic Disorder said in the filing that before BridgeBio's initial public offering, it bought about 167.7 million preferred units of BridgeBio for roughly $170.6 million in a series of financing deals.

The preferred units held by KKR Genetic Disorder were converted into about 34.3 million shares of BridgeBio, KKR Genetic Disorder said.

Price: 33.12, Change: -1.86, Percent Change: -5.30